, but mortality is due to metastatic disease that requires invasion, evasion of immune surveillance, implantation in ectopic sites, continuous replication, cell migration, and angio-genesis. Capturing all of the genetic components that support these cellular processes has been a challenge for cancer ...
The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologiesdigital spatial profilingimmunotherapyspatial profilingtumor microenvironmentImmunotherapies have shown long锕峚sting and unparalleled responses for cancer patients compared to conventional therapy. However, they ...
Predictive biomarkers are discovered and used in oncology research to formulate hypotheses aimed at the identification of patients benefiting from specific therapeutic intervention(s). They pave the way to the development of companion diagnostic tests which are tools readily implemented in the clinic and...
J. Kerr, "Predictive biomarkers: a paradigm shift towards personalized cancer medicine," Nature Reviews Clinical Oncology, vol. 8, no. 10, pp. 587-596, 2011.N. B. la Thangue and D. J. Kerr, "Predictive biomarkers: a paradigm shift towards personalized cancer medicine," Nature Reviews ...
Predictive Biomarkers Present Promise in Immuno-OncologyS. Dangi‐GarimellaThe American Journal of Managed Care
The use of various biomarkers to assess a subject's suitability for treatment with a EGFR/ErbB2 kinase inhibitor for a solid tumor are described. The biomarkers include TGFalpha, pS
Consequently, the evolving landscape of predictive biomarkers in EC has gained importance in daily oncology practice, profoundly changing the role of pathologists. Pathologists are now crucial in interpreting molecular information and participating as members of multidisciplinary teams in therapeutic decisions....
Biomarkers for personalized oncology are used mainly in molecular diagnostics of chronic myeloid leukemia, colon, breast and lung cancer, and recently in melanoma. They are successfully used in the evaluation of the benefits that can be achieved through targeted therapy or in the evaluation of toxic...
Fig. 1. Prognostic, predictive, and on-treatment biomarkers in metastatic melanoma. ctDNA, circulating tumor DNA; IL, interleukin; LAG-3, lymphocyte-activation gene 3; PD-L1, programmed death-ligand 1. The earliest clinical markers that helped to inform prognosis were based on baseline clinical...
The association between pretreatment nutritional status and immunotherapy response in patients with advanced head and neck cancer is unclear. We retrospectively analyzed a cohort of 99 patients who underwent treatment with anti-PD-1 or anti-CTLA-4 antibo